Heart Disease Trial, Recruiting (NCT05332262)

Heart Disease Trial, Recruiting NCT05332262 Sponsor: University of Florida Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05332262 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People with stable coronary artery disease (a long-term narrowing of the heart's arteries) who are scheduled for a planned, non-emergency procedure to open those arteries (called PCI)
Adults aged 18 or older, of any gender
People whose troponin blood test (a marker of heart muscle damage) came back negative before the procedure, or where no troponin test was needed because there were no signs of a heart attack
People who are already taking aspirin as part of their regular heart treatment

Who may not be able to join:

People who are currently having a heart attack at the time of the procedure
People who are currently taking blood-thinning medications called prasugrel or ticagrelor
People who have a known allergy or sensitivity to a blood-thinning medication called clopidogrel
People who receive certain blood-thinning medications given directly into a vein (such as cangrelor or a GPI) during the procedure
People who are not able to give written consent to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 8 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Francesco Franchi, MD, University of Florida College of Medicine Jacksonville

Phone: 9042442060

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05332262

Sponsor: University of Florida

Phase: Not Applicable

Status: Recruiting

Condition: Heart Disease

Trial contact: 9042442060

More information: https://clinicaltrials.gov/study/NCT05332262

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People with stable coronary artery disease (a long-term narrowing of the heart's arteries) who are scheduled for a planned, non-emergency procedure to open those arteries (called PCI)
Adults aged 18 or older, of any gender
People whose troponin blood test (a marker of heart muscle damage) came back negative before the procedure, or where no troponin test was needed because there were no signs of a heart attack
People who are already taking aspirin as part of their regular heart treatment

Who may not be able to join:

People who are currently having a heart attack at the time of the procedure
People who are currently taking blood-thinning medications called prasugrel or ticagrelor
People who have a known allergy or sensitivity to a blood-thinning medication called clopidogrel
People who receive certain blood-thinning medications given directly into a vein (such as cangrelor or a GPI) during the procedure
People who are not able to give written consent to take part in the trial

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 8 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Florida

Registry

ClinicalTrials.gov

Start date

23 May 2022

Est. completion

1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Peri-PCI myocardial infarction or myocardial injury

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov